Q-omics provides the consensus-scored MYOD1 profile across patient tissues and cancer cell-line models. MYOD1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MYOD1 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MYOD1 RNA expression shows 7,889 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UCEC, KIRC, and HNSC as cancer lineages where MYOD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYOD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYOD1 survival associations across molecular data types. MYOD1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYOD1 RNA expression–survival associations across cancer types. High MYOD1 expression shows unfavorable associations in UCEC, THYM, HNSC, ACC and OV, but favorable associations in LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MYOD1 RNA expression.
This table summarizes MYOD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MYOD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYOD1 shows higher tumor expression in KIRC, UCEC and LUSC. The KIRC box plot shows higher MYOD1 RNA expression in tumor versus normal tissue (log2 FC = +0.081, t-test p < 0.001).
This table shows molecular features associated with MYOD1 in patient tissues and cancer cell lines. In patient samples, MYOD1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYOD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Myeloma.
